HAVCR2 and non-small cell lung carcinoma: Although definitive data are still immature, other early reports suggest that the combination of anti-TIM-3 (TSR-022) and anti-PD-1 (TSR-042) has shown activity in NSCLC patients progressing on previous anti-PD-1 therapy (142).